

## **Announcing TIMESPAN**

EASO is pleased to join 16 partners across the world in announcing TIMESPAN - an innovative approach to management of ADHD using Real-World Data.

TIMESPAN's main objective is to advance the management of patients with Attention Deficit Hyperactivity Disorders (ADHD), who also suffer from cardiometabolic disease - including obesity - by improving available treatments and risk stratification.

Emerging evidence points at a strong association and shared genetic traits between adult ADHD and cardiometabolic diseases like Obesity, Type-2 Diabetes and cardiovascular disease, which, when inadequately treated can lead to adverse outcomes and substantial costs for society.

Various national guidelines of cardiometabolic disease already stressed the importance of concurrent psychiatric disorders, however knowledge about appropriate management of cardiometabolic disease in ADHD is lacking. This is problematic given that ADHD is a common and serious condition, which affects between 2 and 5 % of adults.

TIMESPAN seeks to address the main objective using existing large-scale cohort studies and linked electronic health record databases in multiple countries with different health care systems. We also make use of smartphones and wearable devices to obtain novel real-time and data rich measurements of ADHD medication treatment and cardiometabolic risks. The combined use of unparalleled data sources and new technologies for data collection, management and analysis will identify optimized and personalized treatment approaches across multiple disciplines that will minimize harm and maximize positive changes, both in disease prognosis and to improve treatment continuity.

TIMESPAN is expected to improve the clinical outcomes, as well as quality of life in adult ADHD patients with co-occurring cardiometabolic disease first and foremost.

But it will also serve to facilitate developments of new technological tools for advanced data management, monitoring and analytics for European stakeholders.

Finally, TIMESPAN develops dedicated strategies to inform clinicians, patients, health authorities, and the general public, to allow for a sustainable implementation of our findings, like recommendations for treatment guidelines.

## **PARTNERS**

TIMESPAN unites a strong, multidisciplinary team of 17 partners from academia, small and medium-sized enterprises (SMEs), patients and care

providers, including many research groups with a leading international position in their discipline.

The project's scientific coordinator, Prof. Dr. Henrik Larsson is Principal Investigator and Coinvestigator for several national and international grants that focus on the causes and consequences of ADHD. Concentris research management gmbh manages the project and communicates its progress to the public.

1. Aarhus Universitet (AU), Denmark
2. ADD Information Services (ADDISS), United Kingdom
3. concentris research management gmbh (concentris), Germany
4. Empatica SRL (Empatica), Italy
5. Fundació Hospital Universitari Vall d'Hebron - Institut de Recerca (VHIR), Spain
6. Háskóli Íslands (UoI), Iceland
7. Karolinska Institutet (KI), Sweden
8. King s College London (KCL), United Kingdom
9. Örebro University (ORU), Sweden
10. SUNY Upstate Medical University (SUNY), United States of America
11. Tartu Ülikool (UTARTU), Estonia
12. The European Association for the Study of Obesity (EASO), Ireland
13. University College London (UCL), United Kingdom
14. Universitet I Bergen (UiN), Norway
15. University Medical Center Groningen (UMCG), The Netherlands
16. University of New South Wales (UNSW), Australia
17. The University of Hong Kong (HKU), Hong Kong

## **CONTACT**

Prof. Dr. Henrik Larsson  
TIMESPAN Coordinator [henrik.larsson@oru.se](mailto:henrik.larsson@oru.se)  
Dr. Christiana Krammer  
Project Manager  
[christiana.krammer@concentris.de](mailto:christiana.krammer@concentris.de)  
Veronika Pičmanová  
Dissemination Manager  
[veronika.picmanova@concentris.de](mailto:veronika.picmanova@concentris.de)

## **FUNDING**

This project has received funding from the European Union's Horizon 2020 research and innovation program under grant agreement No. 965381. This press release reflects only the view of the author, and the European Commission is not responsible for any use that may be made of the information it contains. Reproduction is authorized provided the source is acknowledged.